Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial

[1]  A. Tomelleri,et al.  Giant cell arteritis: Update on clinical manifestations, diagnosis, and management. , 2022, European journal of internal medicine.

[2]  I. Wicks,et al.  Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2022, Annals of the Rheumatic Diseases.

[3]  E. Matteson,et al.  Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study , 2022, Annals of the Rheumatic Diseases.

[4]  W. Schmidt,et al.  Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial , 2021, Trials.

[5]  G. Guyatt,et al.  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis , 2021, Arthritis & rheumatology.

[6]  J. Springer,et al.  Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica. , 2021, The Medical clinics of North America.

[7]  J. Pope,et al.  A meta-analysis of the epidemiology of giant cell arteritis across time and space , 2020, Arthritis Research & Therapy.

[8]  P. Geusens,et al.  Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study , 2019, ACR open rheumatology.

[9]  A. Deodhar,et al.  Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study , 2019, RMD Open.

[10]  C. Turesson,et al.  2018 Update of the EULAR recommendations for the management of large vessel vasculitis , 2019, Annals of the rheumatic diseases.

[11]  B. Griffiths,et al.  Giant cell arteritis: new concepts, treatments and the unmet need that remains. , 2018, Rheumatology.

[12]  M. Tomšič,et al.  Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. , 2018, Rheumatology.

[13]  L. Sammut,et al.  002 Biopsy proven giant cell arteritis in a patient with psoriatic arthritis on TNF-alpha inhibitor treated with high dose prednisolone and a switch to secukinumab (anti IL-17) , 2018 .

[14]  M. Cid,et al.  Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved , 2018, Rheumatology.

[15]  E. Matteson,et al.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities , 2017, Nature Reviews Rheumatology.

[16]  B. Bonnotte,et al.  Recent advances in our understanding of giant cell arteritis pathogenesis. , 2017, Autoimmunity reviews.

[17]  J. Stone,et al.  Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.

[18]  J. Stone,et al.  An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy , 2016, Annals of the rheumatic diseases.

[19]  S. Reichenbach,et al.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[20]  M. Dougados,et al.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. , 2015, The New England journal of medicine.

[21]  P. Merkel,et al.  Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study , 2015, The Journal of Rheumatology.

[22]  H. Petri,et al.  Incidence of Giant Cell Arteritis and Characteristics of Patients: Data‐Driven Analysis of Comorbidities , 2015, Arthritis care & research.

[23]  A. Gottlieb,et al.  Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) , 2015, The British journal of dermatology.

[24]  Roland Fisch,et al.  Bayesian Design of Proof-of-Concept Trials , 2015, Therapeutic innovation & regulatory science.

[25]  Mahboob Rahman,et al.  Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis , 2012, Annals of the rheumatic diseases.

[26]  B. Bonnotte,et al.  Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[27]  R. Olshen,et al.  Th17 and Th1 T-Cell Responses in Giant Cell Arteritis , 2010, Circulation.

[28]  S. Gabriel,et al.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.

[29]  R. Tomsak.  Giant cell arteritis. , 2002, Ophthalmology.